Fund BasicsSee More
- Fund Family Direxion Investments
- Assets Under Management 137,016,000
- Shares Outstanding, K 1,650
- 60-Month Beta 2.44
- Price/Earnings ttm 24.41
- Annual Dividend & Yield 0.03
- Most Recent Dividend 0.006
- Management Fee 1.08%
|Period||Period Low||Period High||Performance|
| || |
+9.90 (+13.04%)since 03/09/21
| || |
+0.71 (+0.83%)since 01/08/21
| || |
+37.84 (+78.83%)since 04/09/20
Growth investing will also likely to stay strong maintaining the ongoing trend.
Last week witnessed a tug-of-war between bulls and bears.
If investors can identify the trending investing area amid all the coronavirus chaos, they can easily take a leveraged position on that and beat the broader market.
Back-to-Back Gains Help Dow, S&P Soar 12%+ This Week
The Zacks Analyst Blog Highlights: UCO, RUSL, NEED, CURE and YINN
These leveraged ETFs won last week despite a broader market bloodbath.
Vote approving transaction passes with 95% support for the transaction
-- Quorum achieved for OpGen stockholder vote on Curetis business combination with 99% of votes supporting transaction
Shareholder proxy vote achieves quorum with 99% support for the transaction
OpGen, Inc. (Nasdaq: OPGN, "OpGen"), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today an update on shareholder...
|3rd Resistance Point||89.54|
|2nd Resistance Point||87.71|
|1st Resistance Point||86.77|
|1st Support Level||84.00|
|2nd Support Level||82.17|
|3rd Support Level||81.23|